Table 3 Clinical characteristics by brain metastasis and generation of EGFR-TKI.
Number (%) | With brain metastasis | p-value | Without brain metastasis | p-value | ||
|---|---|---|---|---|---|---|
Gefitinib/erlotinib, N = 113 | Afatinib, N = 98 | Gefitinib/erlotinib, N = 130 | Afatinib, N = 212 | |||
Age | ||||||
Mean ± SD | 68.6 ± 11.8 | 62.9 ± 10.3 | < 0.001 | 72.9 ± 12.0 | 63.7 ± 10.7 | < 0.001 |
≥ 65 years old | 74 (65.5) | 43 (43.9) | 0.003 | 101 (77.7) | 94 (44.3) | < 0.001 |
ECOG PS | ||||||
0–1 | 76 (67.3) | 89 (90.8) | 100 (76.9) | 194 (91.5) | ||
≥ 2 | 37 (32.7) | 9 (9.2) | < 0.001 | 30 (23.1) | 18 (8.5) | < 0.001 |
Sex | ||||||
Male | 40 (35.4) | 35 (35.7) | 45 (34.6) | 92 (43.4) | ||
Female | 73 (64.6) | 63 (64.3) | 1.000 | 85 (65.4) | 120 (56.6) | 0.135 |
Smoking history | ||||||
Current/ex-smoker | 27 (23.9) | 23 (23.5) | 34 (26.2) | 43 (20.3) | ||
Never smoker | 86 (76.1) | 75 (76.5) | 1.000 | 96 (73.8) | 169 (79.7) | 0.259 |
Histology | ||||||
Adenocarcinoma | 112 (99.1) | 97 (99.0) | 128 (98.5) | 208 (98.1) | ||
Others | 1 (0.9) | 1 (1.0) | 1.000 | 2 (1.5) | 4 (1.9) | 1.000 |
EGFR mutation | ||||||
L858R | 71 (62.8) | 46 (46.9) | 80 (61.5) | 99 (46.7) | ||
19 deletion | 42 (37.2) | 52 (53.1) | 0.029 | 50 (38.5) | 113 (53.3) | 0.011 |
Liver metastasis | ||||||
Presence | 19 (16.8) | 18 (18.4) | 13 (10.0) | 20 (9.4) | ||
Absence | 95 (83.2) | 80 (81.6) | 0.775 | 117 (90.0) | 192 (90.6) | 1.000 |
